

Beyond AChR

Recognizing and Treating MuSK Ab+, LRP4 Ab+, and Triple Seronegative Myasthenia Gravis

Neelam Goyal, MD

Clinical Professor, Neuromuscular Medicine
Stanford University · Stanford, CA

Christyn Edmundson, MD

Neurologist
Swedish Neuroscience Institute · Seattle, WA

DISTRIBUTION ACROSS MG SUBTYPES

~85% AChR Ab+	~10% Triple Seronegative	~5-7% MuSK Ab+	~1-2% LRP4 Ab+
-------------------------	------------------------------------	--------------------------	--------------------------

AChR dominates diagnosis — but the **~15–20% beyond it** require unique diagnostic and therapeutic approaches.

QUICK REFERENCE

Subtypes at a glance	AChR Ab+ ~85% of cases	Triple Seronegative ~10% of cases	MuSK Ab+ ~5-7% of cases	LRP4 Ab+ ~1-2% of cases
DIAGNOSTIC PRIORITY	Standard serology; CT chest for thymoma	Cell-based AChR assay; RNS/SFEMG required to confirm diagnosis, consider alternative diagnosis (CMS can mimic MG)	MuSK antibody; RNS / SFEMG if pending	LRP4 antibody; RNS/SFEMG required to confirm diagnosis, consider alternative diagnosis (CMS can mimic MG)
KEY MECHANISTIC FEATURES	AChR blockade, crosslinking / internalization, complement activation	No detectable AChR / MuSK / LRP4 Ab by standard assay; ~20% AChR+ on cell-based assay	Disrupts MuSK–LRP4 interaction, impairing AChR clustering via Dok-7	Disrupts AChR clustering via the Dok-7 pathway, complement activation
COMPLEMENT FIXING	YES IgG1 / IgG3	VARIABLE	NO IgG4	YES IgG1 / IgG3
PREFERRED RESCUE THERAPY	PLEX or IVIG	PLEX or IVIG	PLEX (preferred) or IVIG	PLEX or IVIG
PREFERRED TARGETED THERAPY	Complement inhibitors; FcRn inhibitors; Anti-CD19/CD20	Efgartigimod; otherwise standard AChR-like approach	Rituximab (early); FcRn inhibitors; Anti-CD19/CD20	Standard AChR-like approach once confirmed; Efgartigimod

REFERENCES

Narayanaswami P, et al. *Neurol.* 2021;96:114–122. Wolfe GI, et al. *N Engl J Med.* 2016;375:511–522. Howard JF Jr, et al. *Lancet Neurol.* 2021;20:526–536. Nowak RJ, et al. *New Engl J Med.* 2025;392:2309–2320.

ABBREVIATIONS

AChR = acetylcholine receptor · MuSK = muscle-specific kinase · LRP4 = lipoprotein receptor-related protein 4 · CT = computed tomography · RNS = repetitive nerve stimulation · SFEMG = single-fibre electromyography · PLEX = plasma exchange · IVIG = intravenous immunoglobulin · Dok-7 = Docking protein 7

Jointly provided by American Academy of CME, Inc. and CheckRare Inc.

This activity is supported by an educational grant from **argenx**

To view this accredited continuing education activity and complete activity information, visit: checkrare.com/learn/Beyond-AChR